Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2009

View Archived Issues

EMEA accepts for review Schering-Plough's MAA for Sycrest for schizophrenia and bipolar I disorder

Otsuka claims novel collagen production suppressant compounds for cancer treatment

Novel G-protein coupled receptor 40 agonists for the treatment of diabetes discovered by Merck & Co.

Janssen describes adenosine A2A receptor antagonists for the treatment of Parkinson's disease

Nissan Chemical presents P2X7 receptor antagonists for the treatment of rheumatoid arthritis

Dopamine D3 receptor ligands for the treatment of schizophrenia discovered by Abbott

KineMed and Bristol-Myers Squibb sign collaboration agreement in Alzheimer's disease

Meda completes seventh phase III study of azelastine nasal spray for allergic rhinitis

Phase II NT-501 trial demonstrates strong biological effect in retinitis pigmentosa

EMEA grants orphan drug designation for AMT-021 for acute intermittent porphyria

Cytori completes enrollment in PRECISE trial of Celution in chronic myocardial ischemia

Amarillo Biosciences provides update on phase II influenza study in Australia

BioPartners withdraws Biferonex (interferon beta-1a) application from EMEA

Catalyst reports results for phase II CPP-109 trial for cocaine addiction

CSL enters agreements with U.S. and Australian government for swine flu vaccine

FDA approves Besivance for bacterial conjunctivitis

Clinical Data acquires Avalon Pharmaceuticals

AstraZeneca provides regulatory update for Seroquel XR for MDD

Incyte changes primary endpoint for U.S. phase III COMFORT-I trial of INCB-18424

FDA issues complete response letter regarding Johnson & Johnson's NDA for rivaroxaban

Intercell initiates enrollment in phase II clinical trial of VE patch for H5N1 influenza

MediciNova amends dosing regimen for phase II MN-221-CL-007 trial of MN-221 in asthma

Target inhibition seen with Akt inhibitor MK-2206 in solid tumor patients

Phase I data on GDC-0941 in solid tumors reported

Oncolytic virus active in patients with neuroendocrine cancers

TAL-6004 safe and well tolerated in patients with alpha1-antitrypsin deficiency

Recently developed CRTH2 antagonist decreases allergic rhinitis responses in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...